An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary) ; Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms ODIN-BM
- Sponsors AstraZeneca
- 05 Nov 2019 Planned End Date changed from 29 Jan 2020 to 26 Feb 2020.
- 05 Nov 2019 Planned primary completion date changed from 29 Jan 2020 to 26 Feb 2020.
- 10 Sep 2019 Preliminary results (n=3) presented at the 20th World Conference on Lung Cancer